<code id='9874892FA4'></code><style id='9874892FA4'></style>
    • <acronym id='9874892FA4'></acronym>
      <center id='9874892FA4'><center id='9874892FA4'><tfoot id='9874892FA4'></tfoot></center><abbr id='9874892FA4'><dir id='9874892FA4'><tfoot id='9874892FA4'></tfoot><noframes id='9874892FA4'>

    • <optgroup id='9874892FA4'><strike id='9874892FA4'><sup id='9874892FA4'></sup></strike><code id='9874892FA4'></code></optgroup>
        1. <b id='9874892FA4'><label id='9874892FA4'><select id='9874892FA4'><dt id='9874892FA4'><span id='9874892FA4'></span></dt></select></label></b><u id='9874892FA4'></u>
          <i id='9874892FA4'><strike id='9874892FA4'><tt id='9874892FA4'><pre id='9874892FA4'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          hotspot

          author:leisure time    - browse:841
          US Capitol - SOTU
          Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

          WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

          It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

          advertisement

          Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge